Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. grew its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 256.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 429,887 shares of the company’s stock after acquiring an additional 309,239 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Dr. Reddy’s Laboratories were worth $6,788,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in RDY. Robeco Institutional Asset Management B.V. lifted its holdings in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Dr. Reddy’s Laboratories by 382.9% during the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company’s stock worth $148,717,000 after purchasing an additional 7,467,979 shares during the period. Aikya Investment Management Ltd boosted its stake in Dr. Reddy’s Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock worth $88,590,000 after purchasing an additional 4,523,303 shares during the period. Dimensional Fund Advisors LP boosted its stake in Dr. Reddy’s Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company’s stock worth $84,643,000 after purchasing an additional 4,301,212 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Dr. Reddy’s Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after purchasing an additional 3,911,404 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Stock Up 1.8%

Shares of NYSE RDY opened at $14.39 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89. The firm has a 50-day moving average price of $13.39 and a 200 day moving average price of $14.04. The stock has a market capitalization of $12.01 billion, a price-to-earnings ratio of 22.91 and a beta of 0.33.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.02. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Equities research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 8th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.